Notably, co-inhibition of BCL2 and MCL1 in vitro partially abrogated observed resistance in TP53-mutated AML, suggesting combined anti-apoptotic protein inhibition could be effective in this high-risk patient subgroup [29]. This evidence concerns the gene BCL2 and acute myeloid leukemia.